Approaches to minimize infection risk in blood banking and transfusion practice

Infectious Disorders - Drug Targets

Volumn 11, Issue 1, 2011, Pages 45-56

  Lindholm, Paul F ^a   Annen, Kyle ^a   Ramsey, Glenn ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Bacterial contamination; Emerging infectious agents; Infection risk; Leukocytes; Pathogen inactivation; Screening; Sepsis; Transfusion

Indexed keywords

BACTERIAL DNA; BACTERIAL RNA; HEPATITIS DELTA ANTIGEN; LIPOPOLYSACCHARIDE; METHYLENE BLUE; PSORALEN; RIBOFLAVIN; THROMBOCYTE CONCENTRATE;

ARTICLE; BABESIOSIS; BACILLUS CEREUS; BACTERIUM CONTAMINATION; BACTERIUM ISOLATION; BLOOD BANK; BLOOD SAFETY; BLOOD TRANSFUSION; BORRELIA BURGDORFERI; BOVINE SPONGIFORM ENCEPHALOPATHY; BURKHOLDERIA CEPACIA; CHAGAS DISEASE; CREUTZFELDT JAKOB DISEASE; CROSS LINKING; CYTOMEGALOVIRUS; DENGUE; EHRLICHIOSIS; EPSTEIN BARR VIRUS; ERYTHROCYTE TRANSFUSION; HEPATITIS A; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS E; HEPATITIS VIRUS; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN T CELL LEUKEMIA VIRUS 1; HUMAN T CELL LEUKEMIA VIRUS 2; IMMUNOASSAY; IMMUNOCOMPROMISED PATIENT; INFECTION RISK; KAPOSI SARCOMA; LYME DISEASE; MALARIA; NONHUMAN; NUCLEIC ACID ANALYSIS; POSTTRANSFUSION HEPATITIS; PSEUDOMONAS AERUGINOSA; QUANTITATIVE ANALYSIS; RICKETTSIA RICKETTSII; SCREENING TEST; SEPSIS; SEROPREVALENCE; SERRATIA MARCESCENS; STAPHYLOCOCCUS EPIDERMIDIS; SYPHILIS; THROMBOCYTE TRANSFUSION; TREPONEMA PALLIDUM; VIRUS TRANSMISSION; WEST NILE FLAVIVIRUS;

EID: 79551622159     PISSN: 18715265     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152611794407746     Document Type: Article

References (112)

1. Ceccherini-Nelli, L.; Filipponi, F.; Mosca, F.; Campa, M. The risk of contracting an infectious disease from blood transfusion. Transplant. Proc., 2004, 36(3), 680-682.
2. Wang, B.; Schreiber, G. B.; Glynn, S. A.; Kleinman, S.; Wright, D. J.; Murphy, E. L.; Busch, M. P. Retrovirus Epidemiology Donor Study. Does prevalence of transfusion-transmissible viral infection reflect corresponding incidence in United States blood donors? Transfusion, 2005, 45(7), 1089-1096.
3. Circular of Information for the Use of Human Blood and Blood Components. 2009 http://www.aabb.org/Documents/About_Blood/Circulars_of_Information/coi0809r.pdf
4. Fiebig, E.; Busch, M. Infectious Disease Screening. 16th ed.; American Association of Blood Banks: Bethesda, 2008; pp. 241-282.
5. Busch, M. P. Transfusion-transmitted viral infections: building bridges to transfusion medicine to reduce risks and understand epidemiology and pathogenesis. Transfusion, 2006, 46(9), 1624-1640.
6. U.S.F.D.A. Guidance for Industry-Recommendations for Management of Donors at Increased Risk for Human Immunodeficiency Virus Type 1 (HIV-1) Group O Infection. 2009 http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Blood/ucm180817.htm
7. Beeson, P. Jaundice Occurring One to Four Months After Transfusion of Blood or Plasma. Report of Seven Cases. J. Am. Med. Assoc., 1943, 121, 1332-1334.
8. Barbara, J.; Dow, B. Retroviruses and Other Viruses. 4th ed.; Wiley-Blackwell, USA. 2009, pp. 746-759.
9. Alter, H.; Esteban-Mur, J. Transfusion-Transmitted Hepatitis. 4th ed.; Wiley-Blackwell, USA: 2009, pp. 718-745.
10. Klein, H.; Anstee, D. Infectious agents transmitted by transfusion. 11th ed.; Wiley-Blackwell, USA, 2005, Vol. 1, pp. 701-773.
11. Kleinman, S. H.; Busch, M. P. Assessing the impact of HBV NAT on window period reduction and residual risk. J. Clin. Virol., 2006, 36 (Suppl 1), S23-9.
12. Cannon, M. J.; Operskalski, E. A.; Mosley, J. W.; Radford, K.; Dollard, S. C. Lack of evidence for human herpesvirus-8 transmission via blood transfusion in a historical US cohort. J. Infect. Dis., 2009, 199(11), 1592-1598.
13. Smith, D.; Lu, Q.; Yuan, S.; Goldfinger, D.; Fernando, L.; Ziman, A. Survey of current practice for prevention of transfusion-transmitted cytomegalovirus in the United States: leucoreduction vs. cytomegalovirus-seronegative. Vox Sang., 2010, 98(1), 29-36.
14. Ziemann, M.; Krueger, S.; Maier, A. B.; Unmack, A.; Goerg, S.; Hennig, H. High prevalence of cytomegalovirus DNA in plasma samples of blood donors in connection with seroconversion. Transfusion, 2007, 47(11), 1972-1983.
15. Allain, J.-P.; Stramer, S. L.; Carneiro-Proietti, A. B. F.; Martins, M. L.; Lopes da Silva, S. N.; Ribeiro, M.; Proietti, F. A.; Reesink, H. W. Transfusion-transmitted infectious diseases. Biologicals, 2009, 37(2), 71-77.
16. Kuehnert, M. J.; Roth, V. R.; Haley, N. R.; Gregory, K. R.; Elder, K. V.; Schreiber, G. B.; Arduino, M. J.; Holt, S. C.; Carson, L. A.; Banerjee, S. N.; Jarvis, W. R. Transfusion-transmitted bacterial infection in the United States, 1998 through 2000. Transfusion, 2001, 41(12), 1493-1499.
17. Theakston, E. P.; Morris, A. J.; Streat, S. J.; Baker, B. W.; Woodfield, D. G. Transfusion transmitted Yersinia enterocolitica infection in New Zealand. Aust. N Z. J. Med., 1997, 27(1), 62-67.
18. Barrett, B. B.; Andersen, J. W.; Anderson, K. C. Strategies for the avoidance of bacterial contamination of blood components. Transfusion, 1993, 33(3), 228-233.
19. Dzieczkowski, J. S.; Barrett, B. B.; Nester, D.; Campbell, M.; Cook, J.; Sugrue, M.; Andersen, J. W.; Anderson, K. C. Characterization of reactions after exclusive transfusion of white cell-reduced cellular blood components. Transfusion, 1995, 35(1), 20-25.
20. Park, Y. A.; Brecher, M. E. Bacterial Contamination of Blood Products. 4th ed.; Wiley-Blackwell, USA 2009, pp. 773-790.
21. Richards, C.; Kolins, J.; Trindade, C. D. Autologous transfusiontransmitted Yersinia enterocolitica. JAMA, 1992, 268(12), 154-152.
22. Sire, J. M.; Michelet, C.; Mesnard, R.; Tardivel, R.; Minet, J.; Bracq, H.; Avril, J. L. Septic shock due to Yersinia enterocolitica after autologous transfusion. Clin. Infect. Dis., 1993, 17(5), 954-955.
23. Haditsch, M.; Binder, L.; Gabriel, C.; Muller-Uri, P.; Watschinger, R.; Mittermayer, H. Yersinia enterocolitica septicemia in autologous blood transfusion. Transfusion, 1994, 34(10), 907-909.
24. Benavides, S.; Nicol, K.; Koranyi, K.; Nahata, M. C. Yersinia septic shock following an autologous transfusion in a pediatric patient. Transfus. Apher. Sci., 2003, 28 (1), 19-23.
25. Duncan, K. L.; Ransley, J.; Elterman, M. Transfusion-transmitted Serratia liquifaciens from an autologous blood unit. Transfusion, 1994, 34(8), 738-739.
26. Niu, M. T.; Knippen, M.; Simmons, L.; Holness, L. G. Transfusion-transmitted Klebsiella pneumoniae fatalities, 1995 to 2004. Transfus. Med. Rev., 2006, 20(2), 149-157.
27. McAllister, S. K.; Bland, L. A.; Arduino, M. J.; Aguero, S. M.; Wenger, P. N.; Jarvis, W. R. Patient cytokine response in transfusion-associated sepsis. Infect. Immun., 1994, 62(5), 2126-2128.
28. Schwalbe, B.; Spath-Schwalbe, E. Endotoxin concentrations and cytokine responses in a patient with fatal transfusion-associated sepsis. Transfusion, 1998, 38(7), 703-705.
29. Centers for Disease, Control and Prevention Update. Yersinia enterocolitica bacteremia and endotoxin shock associated with red blood cell transfusions--United States, 1991. MMWR-Morb. Mortal. Wkly Rep., 1991, 40(11), 176-178.
30. Yomtovian, R.; Palavecino, E. Bacterial contamination of blood components-history and epidemiology. American Association of Blood Banks: Bethesda, MD, 2003, pp. 1-30.
31. Grossman, B. J.; Kollins, P.; Lau, P. M.; Perreten, J. L.; Bowman, R. J.; Malcolm, S.; Palko, W. M. Screening blood donors for gastrointestinal illness: a strategy to eliminate carriers of Yersinia enterocolitica. Transfusion, 1991, 31(6), 500-501.
32. Arduino, M. J.; Bland, L. A.; Tipple, M. A.; Aguero, S. M.; Favero, M. S.; Jarvis, W. R. Growth and endotoxin production of Yersinia enterocolitica and Enterobacter agglomerans in packed erythrocytes. J. Clin. Microbiol., 1989, 27(7), 1483-1485.
33. Blajchman, M. A.; Beckers, E. A. M.; Dickmeiss, E.; Lin, L.; Moore, G.; Muylle, L. Bacterial detection of platelets: current problems and possible resolutions. Transfus. Med. Rev., 2005, 19(4), 259-272.
34. Hillyer, C. D.; Josephson, C. D.; Blajchman, M. A.; Vostal, J. G.; Epstein, J. S.; Goodman, J. L. Bacterial contamination of blood components: risks, strategies, and regulation: joint ASH and AABB educational session in transfusion medicine. Hematology, 2003, 575-589.
35. Yomtovian, R.; Tomasulo, P.; Jacobs, M. R. Platelet bacterial contamination: assessing progress and identifying quandaries in a rapidly evolving field. Transfusion, 2007, 47(8), 1340-1346.
36. Klein, H. G.; Dodd, R. Y.; Ness, P. M.; Fratantoni, J. A.; Nemo, G. J. Current status of microbial contamination of blood components: summary of a conference. Transfusion, 1997, 37(1), 95-101.
37. Brecher, M. E.; Hay, S. N.; Rose, A. D.; Rothenberg, S. J. Evaluation of BacT/ALERT plastic culture bottles for use in testing pooled whole blood-derived leukoreduced platelet-rich plasma platelets with a single contaminated unit. Transfusion, 2005, 45(9), 1512-1517.
38. Brecher, M. E.; Hay, S. N. Bacterial contamination of blood components. Clin. Microbiol. Rev., 2005, 18(1), 195-204.
39. Perez, P.; Salmi, L. R.; Follea, G.; Schmit, J. L.; de Barbeyrac, B.; Sudre, P.; Salamon, R.; BACTHEM Group; French Hemovigilance Network. Determinants of transfusion-associated bacterial contamination: results of the French BACTHEM Case-Control Study. Transfusion, 2001, 41(7), 862-872.
40. Ness, P.; Braine, H.; King, K.; Barrasso, C.; Kickler, T.; Fuller, A.; Blades, N. Single-donor platelets reduce the risk of septic platelet transfusion reactions. Transfusion, 2001, 41(7), 857-861.
41. Engelfriet, C. P.; Reesink, H. W.; Blajchman, M. A.; Muylle, L.; Kjeldsen-Kragh, J.; Kekomaki, R.; Yomtovian, R.; Hocker, P.; Stiegler, G.; Klein, H. G.; Soldan, K.; Barbara, J.; Slopecki, A.; Robinson, A.; Seyfried, H. Bacterial contamination of blood components. Vox Sang., 2000, 78(1), 59-67.
42. Goldman, M.; Blajchman, M. A. Blood product-associated bacterial sepsis. Transfus. Med. Rev., 1991, 5 (1), 73-83.
43. Goldman, M.; Roy, G.; Frechette, N.; Decary, F.; Massicotte, L.; Delage, G. Evaluation of donor skin disinfection methods. Transfusion, 1997, 37(3), 309-312.
44. McDonald, C. P.; Lowe, P.; Roy, A.; Robbins, S.; Hartley, S.; Harrison, J. F.; Slopecki, A.; Verlander, N.; Barbara, J. A. Evaluation of donor arm disinfection techniques. Vox Sang., 2001, 80(3), 135-141.
45. McDonald, C. P. Bacterial risk reduction by improved donor arm disinfection, diversion and bacterial screening. Transfus. Med., 2006, 16(6), 381-396.
46. Simon, T. L.; Nelson, E. J.; Murphy, S. Extension of platelet concentrate storage to 7 days in second-generation bags. Transfusion, 1987, 27(1), 6-9.
47. Heal, J. M.; Singal, S.; Sardisco, E.; Mayer, T. Bacterial proliferation in platelet concentrates. Transfusion, 1986, 26(4), 388-390.
48. Hay, S. N.; Immel, C. C.; McClannan, L. S.; Brecher, M. E. The introduction of 7-day platelets: a university hospital experience. J. Clin. Apher., 2007, 22(5), 283-286.
49. Kleinman, S.; Dumont, L. J.; Tomasulo, P.; Bianco, C.; Katz, L.; Benjamin, R. J.; Gajic, O.; Brecher, M. E. The impact of discontinuation of 7-day storage of apheresis platelets (PASSPORT) on recipient safety: an illustration of the need for proper risk assessments. Transfusion, 2009, 49(5), 903-912.
50. Shulman, I. A. College of American Pathologists Laboratory Accreditation checklist item TRM.44955. Phase I requirement on bac terial detection in platelets. Arch. Pathol. Lab. Med., 2004, 128(9), 958-963.
51. Silva, M. A., Ed., Standards for blood banks and transfusion services. 24th ed.; American Association of Blood Banks: Bethesda, MD, 2006.
52. Brecher, M. E.; Boothe, G.; Kerr, A. The use of a chemiluminescence-linked universal bacterial ribosomal RNA gene probe and blood gas analysis for the rapid detection of bacterial contamination in white cell-reduced and nonreduced platelets. Transfusion, 1993, 33(6), 450-457.
53. Burgess, S. Food and Drug Administration. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm190490.htm (accessed Dec 10, 2009), 2009.
54. Yomtovian, R., Bacterial contamination of blood: lessons from the past and road map for the future. Transfusion, 2004, 44(3), 450-460.
55. Schmidt, M.; Hourfar, M. K.; Nicol, S.-B.; Wahl, A.; Heck, J.; Weis, C.; Tonn, T.; Spengler, H.-P.; Montag, T.; Seifried, E.; Roth, W. K. A comparison of three rapid bacterial detection methods under simulated real-life conditions. Transfusion, 2006, 46 (8), 1367-1373.
56. Mohammadi, T.; Pietersz, R. N. I.; Vandenbroucke-Grauls, C. M. J. E.; Savelkoul, P. H. M.; Reesink, H. W. Detection of bacteria in platelet concentrates: comparison of broad-range real-time 16S rDNA polymerase chain reaction and automated culturing. Transfusion, 2005, 45(5), 731-736.
57. Brecher, M. E.; Hay, S. N.; Rothenberg, S. J. Validation of BacT/ALERT plastic culture bottles for use in testing of wholeblood-derived leukoreduced platelet-rich-plasma-derived platelets. Transfusion, 2004, 44(8), 1174-1178.
58. Kleinman, S. H.; Kamel, H. T.; Harpool, D. R.; Vanderpool, S. K.; Custer, B.; Wiltbank, T. B.; Nguyen, K.-A.; Tomasulo, P. A. Twoyear experience with aerobic culturing of apheresis and whole blood-derived platelets. Transfusion, 2006, 46(10), 1787-1794.
59. Pietersz, R. N. I.; Engelfriet, C. P.; Reesink, H. W.; Wood, E. M.; Winzar, S.; Keller, A. J.; Wilson, J. T.; Henn, G.; Mayr, W. R.; Ramirez-Arcos, S.; Goldman, M.; Georgsen, J.; Morel, P.; Herve, P.; Andeu, G.; Assal, A.; Seifried, E.; Schmidt, M.; Foley, M.; Doherty, C.; Coakley, P.; Salami, A.; Cadden, E.; Murphy, W. G.; Satake, M.; de Korte, D.; Bosnes, V.; Kjeldsen-Kragh, J.; McDonald, C.; Brecher, M. E.; Yomtovian, R.; AuBuchon, J. P. Detection of bacterial contamination of platelet concentrates. Vox Sang., 2007, 93(3), 260-277.
60. Casewell, M. W.; Slater, N. G.; Cooper, J. E. Operating theatre water-baths as a cause of pseudomonas septicaemia. J. Hosp. Infect., 1981, 2(3), 237-47.
61. Wang, S. A.; Tokars, J. I.; Bianchine, P. J.; Carson, L. A.; Arduino, M. J.; Smith, A. L.; Hansen, N. C.; Fitzgerald, E. A.; Epstein, J. S.; Jarvis, W. R. Enterobacter cloacae bloodstream infections traced to contaminated human albumin. Clin. Infect. Dis., 2000, 30(1), 35-40.
62. Steere, A. C.; Tenney, J. H.; Mackel, D. C.; Snyder, M. J.; Polakavetz, S.; Dunne, M. E.; Dixon, R. Pseudomonas species bacteremia caused by contaminated normal human serum albumin. J. Infect. Dis., 1977, 135(5), 729-735.
63. Chambers, R. W.; Foley, H. T.; Schmidt, P. J. Transmission of syphilis by fresh blood components. Transfusion, 1969, 9(1), 32-34.
64. Soendjojo, A.; Boedisantoso, M.; Ilias, M. I.; Rahardjo, D. Syphilis d'emblee due to blood transfusion. Case report. Br. J. Venereal Dis., 1982, 58(3), 149-150.
65. Risseeuw-Appel, I. M.; Kothe, F. C. Transfusion syphilis: a case report. Sex. Transmit. Dis., 1983, 10(4), 200-201.
66. Orton, S. Syphilis and blood donors: what we know, what we do not know, and what we need to know. Transfus. Med. Rev., 2001, 15(4), 282-291.
67. Cable, R. G.; Leiby, D. A. Risk and prevention of transfusiontransmitted babesiosis and other tick-borne diseases. Curr. Opin. Hematol., 2003, 10(6), 405-411.
68. Arguin, P. M.; Singleton, J.; Rotz, L. D.; Marston, E.; Treadwell, T. A.; Slater, K.; Chamberland, M.; Schwartz, A.; Tengelsen, L.; Olson, J. G.; Childs, J. E. An investigation into the possibility of transmission of tick-borne pathogens via blood transfusion. Transfusion-associated tick-borne illness task force. Transfusion, 1999, 39(8), 828-833.
69. McKechnie, D. B.; Slater, K. S.; Childs, J. E.; Massung, R. F.; Paddock, C. D. Survival of Ehrlichia chaffeensis in refrigerated, ADSOL-treated RBCs. Transfusion 2000, 40(9), 1041-1047.
70. Wells, G. M.; Woodward, T. E.; Fiset, P.; Hornick, R. B. Rocky mountain spotted fever caused by blood transfusion. JAMA, 1978, 239(26), 2763-2765.
71. Stramer, S. L.; Hollinger, F. B.; Katz, L. M.; Kleinman, S.; Metzel, P. S.; Gregory, K. R.; Dodd, R. Y. Emerging infectious disease agents and their potential threat to transfusion safety. Transfusion, 2009, 49 (Suppl 2), 1S-29S.
72. Coste, J.; Prowse, C.; Eglin, R.; Fang, C.; Subgroup on, T. S. E. A report on transmissible spongiform encephalopathies and transfusion safety. Vox Sang., 2009, 96, (4), 284-91.
73. Fourth case of transfusion-associated variant-CJD. In: Health Protection Report, Health Protection Agency, 2007, vol. 1, pp. 2-3.
74. Post mortem finding of asymptomatic variant Creutzfeldt-Jakob Disease abnormal prion protein in a person with haemophilia. In Health Protection Report, Health Protection Agency, 2009; Vol. 3, p. 1.
75. Centers for Disease Control and Prevention. Fact sheet: variant Creutzfeldt-Jakob disease. 2010 http://www.cdc.gov/ncidod/dvrd/vcjd/factsheet_nvcjd.htm
76. Food and Drug Administration. Questions and answers on "Guidance for industry: revised preventive measures to reduce the possible risk of transmission of Creutzfeldt-Jakob disease (CJD) and variant Creutzfeldt-Jakob disease (vCJD) by blood and blood products" 2010 http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Blood/ucm074100.htm
77. NHS Blood and Transplant. Board paper 09/89. National commissioning of blood, components and specialist services 2010/11 2009 http://www.nhsbt.nhs.uk/downloads/board_papers/nov09/ncg_09_89.pdf
78. Wiltshire, M.; Thomas, S.; Scott, J.; Hicks, V.; Haines, M.; Cookson, P.; Garwood, M.; Cardigan, R. Prion reduction of red blood cells: impact on component quality. Transfusion 2010, 50(5), 970-979.
79. Centers for Disease Control and Prevention. Chronic wasting disease (CWD) 2010 http://www.cdc.gov/ncidod/dvrd/cwd/
80. Gubernot, D. M.; Lucey, C. T.; Lee, K. C.; Conley, G. B.; Holness, L. G.; Wise, R. P. Babesia infection through blood transfusions: reports received by the US Food and Drug Administration, 1997-2007. Clin. Infect. Dis., 2009, 48(1), 25-30.
81. Johnson, S.; Cable, R.; Tonnetti, L.; Spencer, B.; Rios, J.; Leiby, D. Seroprevalence of Babesia microti in blood donors from Babesiaendemic areas of the northeastern United States: 2000 through 2007. Transfusion, 2009, 49(12), 2574-2582.
82. Gubernot, D.; Nakhasi, H.; Mied, P.; Asher, D.; Epstein, J.; Kumar, S. Transfusion-transmitted babesiosis in the United States: summary of a workshop. Transfusion [Online early access] 2009.
83. Teo, D.; Ng, L. C.; Lam, S. Is dengue a threat to the blood supply? Transfus. Med., 2009, 19 (2), 66-77.
84. Mohammed, H.; Linnen, J. M.; Munoz-Jordan, J. L.; Tomashek, K.; Foster, G.; Broulik, A. S.; Petersen, L.; Stramer, S. L. Dengue virus in blood donations, Puerto Rico, 2005. Transfusion, 2008, 48, (7), 1348-1354.
85. Schmunis, G. A. Prevention of transfusional Trypanosoma cruzi infection in Latin America. Memorias do Instituto Oswaldo Cruz, 1999, 94 (Suppl 1), 93-101.
86. Young, C.; Losikoff, P.; Chawla, A.; Glasser, L.; Forman, E. Transfusion-acquired Trypanosoma cruzi infection. Transfusion, 2007, 47(3), 540-544.
87. Stramer, S. In: ARC experience with blood donor screening for T. cruzi, Food and Drug Administration Blood Products Advisory Committee, 94th meeting, Gaithersburg, MD, [Online] April 1, Gaithersburg, MD, 2009; p. 316.
88. Mali, S.; Steele, S.; Slutsker, L.; Arguin, P. M. Centers for Disease Control and, P., Malaria surveillance--United States, 2007. Morb. Mortal.Wkly. Rep. Surveill. Summ. 2009, 58, (5), 1-16.
89. Price, T. Standards for Blood Banks and Transfusion Services. 25th ed.; American Association of Blood Banks: Bethesda, MD, 2008.
90. Food and Drug Administration. Biological product and HCT/P deviation reports-annual summary for fiscal year 2008. 2010 http://www.fda.gov/downloads/BiologicsBloodVaccines/Safety Availability/ReportaProblem/BiologicalProductDeviations/UCM170057.pdf
91. Solheim, B. G.; Cid, J.; Osselaer, J. C. Pathogen reduction technologies. American Association of Blood Banks: Bethesda, MD, 2006; pp. 103-148.
92. Solheim, B. G.; Seghatchian, J. Pathogen Inactivation. 4th ed.; Wiley-Blackwell, USA, 2009; pp. 801-810.
93. Solheim, B. G.; Rollag, H.; Svennevig, J. L.; Arafa, O.; Fosse, E.; Bergerud, U. Viral safety of solvent/detergent-treated plasma. Transfusion, 2000, 40(1), 84-90.
94. Rollag, H.; Solheim, B. G.; Svennevig, J. L. Viral safety of blood derivatives by immune neutralization. Vox Sang., 1998, 74 (Suppl 1), 213-217.
95. Burnouf, T.; Goubran, H. A.; Radosevich, M.; Sayed, M. A.; Gorgy, G.; El-Ekiaby, M. Impact of Triton X-100 on alpha 2-antiplasmin (SERPINF2) activity in solvent/detergent-treated plasma. Biologicals, 2007, 35(4), 349-353.
96. Hellstern, P. Solvent/detergent-treated plasma: composition, efficacy, and safety. Curr. Opin. Hematol., 2004, 11(5), 346-350.
97. Yarranton, H.; Cohen, H.; Pavord, S. R.; Benjamin, S.; Hagger, D.; Machin, S. J. Venous thromboembolism associated with the management of acute thrombotic thrombocytopenic purpura. Br. J. Haematol., 2003, 121(5), 778-785.
98. Wagner, S. J. Virus inactivation in blood components by photoactive phenothiazine dyes. Transfus. Med. Rev., 2002, 16(1), 61-66.
99. Solheim, B. G.; Seghatchian, J. Update on pathogen reduction technology for therapeutic plasma: an overview. Transfus. Apher. Sci., 2006, 35(1), 83-90.
100. Seghatchian, J.; Krailadsiri, P. What's happening? The quality of methylene blue treated FFP and cryo. Transfus. Apher. Sci., 2001, 25(3), 227-231.
101. Krailadsiri, P.; Seghatchian, J.; Macgregor, I.; Drummond, O.; Perrin, R.; Spring, F.; Prescott, R.; Williamson, L.; Prowse, C.; Anstee, D.; Turner, M. The effects of leukodepletion on the generation and removal of microvesicles and prion protein in blood components. Transfusion, 2006, 46(3), 407-417.
102. Politis, C.; Kavallierou, L.; Hantziara, S.; Katsea, P.; Triantaphylou, V.; Richardson, C.; Tsoutsos, D.; Anagnostopoulos, N.; Gorgolidis, G.; Ziroyannis, P. Quality and safety of fresh-frozen plasma inactivated and leucoreduced with the Theraflex methylene blue system including the Blueflex filter: 5 years' experience. Vox Sang., 2007, 92(4), 319-326.
103. Alvarez-Larran, A.; Del Rio, J.; Ramirez, C.; Albo, C.; Pena, F.; Campos, A.; Cid, J.; Muncunill, J.; Sastre, J. L.; Sanz, C.; Pereira, A. Methylene blue-photoinactivated plasma vs. fresh-frozen plasma as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura. Vox Sang., 2004, 86(4), 246-251.
104. Pelletier, J. P. R.; Transue, S.; Snyder, E. L. Pathogen inactivation techniques. Bailliere's Best Pract. Clin. Haematol., 2006, 19(1), 205-242.
105. Hambleton, J.; Wages, D.; Radu-Radulescu, L.; Adams, M.; MacKenzie, M.; Shafer, S.; Lee, M.; Smyers, J.; Wiesehahn, G.; Corash, L. Pharmacokinetic study of FFP photochemically treated with amotosalen (S-59) and UV light compared to FFP in healthy volunteers anticoagulated with warfarin. Transfusion, 2002, 42(10), 1302-1307.
106. Singh, Y.; Sawyer, L. S.; Pinkoski, L. S.; Dupuis, K. W.; Hsu, J. C.; Lin, L.; Corash, L. Photochemical treatment of plasma with amotosalen and long-wavelength ultraviolet light inactivates pathogens while retaining coagulation function. Transfusion, 2006, 46(7), 1168-1177.
107. Apelseth, T. O.; Bruserud, O.; Wentzel-Larsen, T.; Bakken, A. M.; Bjorsvik, S.; Hervig, T. In vitro evaluation of metabolic changes and residual platelet responsiveness in photochemical treated and gamma-irradiated single-donor platelet concentrates during longterm storage. Transfusion, 2007, 47(4), 653-665.
108. McCullough, J.; Vesole, D. H.; Benjamin, R. J.; Slichter, S. J.; Pineda, A.; Snyder, E.; Stadtmauer, E. A.; Lopez-Plaza, I.; Coutre, S.; Strauss, R. G.; Goodnough, L. T.; Fridey, J. L.; Raife, T.; Cable, R.; Murphy, S.; Howard, F. T.; Davis, K.; Lin, J.-S.; Metzel, P.; Corash, L.; Koutsoukos, A.; Lin, L.; Buchholz, D. H.; Conlan, M. G. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial. Blood, 2004, 104(5), 1534-1541.
109. Goodrich, R. P.; Edrich, R. A.; Li, J.; Seghatchian, J., The Mirasol PRT system for pathogen reduction of platelets and plasma: an overview of current status and future trends. Transfus. Apher. Sci. 2006, 35(1), 5-17.
110. Corash, L., Inactivation of viruses, bacteria, protozoa and leukocytes in platelet and red cell concentrates. Vox Sang., 2000, 78, (Suppl 2), 205-210.
111. Solheim, B. G. Pathogen reduction of blood components. Transfus. Apher. Sci., 2008, 39(1), 75-82.
112. Benjamin, R. J.; McCullough, J.; Mintz, P. D.; Snyder, E.; Spotnitz, W. D.; Rizzo, R. J.; Wages, D.; Lin, J.-S.; Wood, L.; Corash, L.; Conlan, M. G. Therapeutic efficacy and safety of red blood cells treated with a chemical process (S-303) for pathogen inactivation: a Phase III clinical trial in cardiac surgery patients. Transfusion, 2005, 45 (11), 1739-1749.